Fig. 7: CA3 and verteporfin inhibit the PAF1/YAP1/TEAD4-mediated transcriptional activation of SOX9 in PC development.
From: PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer
A Confocal images of immunofluorescence staining for PAF1 co-expression with YAP1 and SOX9 in the presence and absence of CA3 (1 µM, 48 h) or verteporfin (2 µM, 48 h) treatment in KC6141 cells. B, C 8xTEAD luciferase and SOX9 promoter activity luciferase assays KC cells treated with CA3 or vehicle control. The bar graphs show activities of 8xTEAD synthetic and SOX9 promoters represented as the percentage of control (DMSO). Data are mean ± SD, n = 3. Significance was determined with a student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001, ns: non-significant, p > 0.05. D ChIP-re-ChIP assay was performed in MiaPaCa2 cells treated with DMSO or CA3 (1 µM, 48 h) or verteporfin (2 µM, 48 h) using PAF1, YAP1, and control IgG antibodies using primers that amplify SOX9 promoter. Immunoprecipitated and purified DNA was amplified using PCR followed by agarose gel electrophoresis. E Schematic shows the overall summary of the study.
